On October 11, Harbin Pharmaceutical Group Co., Ltd. issued an announcement disclosing that the company had recently received a "Notice of Case Filing" and a "Notice of Detention" from a supervisory commission, and that company director and president Lu Chuanyou has been placed under investigation and subjected to detention measures.
The announcement shows that Lu Chuanyou currently serves as a member of the Party Committee of Harbin Pharmaceutical Group, a director of the tenth board of directors, a member of the board's strategy and sustainable development committee, and president. He has held positions within the Harbin Pharmaceutical system for many years, with a career rooted in pharmaceutical production and corporate management roles. He successively served as chief engineer, executive deputy factory director, factory director, and Party secretary of Harbin Pharmaceutical Group Pharmaceutical Factory No. 6, and as Party secretary, chairman, and general manager of Harbin Pharmaceutical Group Sanjing Pharmaceutical Co., Ltd. He also previously served as vice president and senior advisor of Harbin Pharmaceutical Group, and is familiar with the operations of the group's core business segments.
In terms of compensation data, Lu Chuanyou received a total pre-tax remuneration of 2.9668 million yuan from Harbin Pharmaceutical during the 2025 reporting period.
After the incident came to light, Harbin Pharmaceutical emphasized in its announcement that the company has a well-established organizational structure and a standardized governance system, and has always conducted its operations and governance in accordance with the Company Law, the Code of Corporate Governance for Listed Companies, Shanghai Stock Exchange listing rules, and the company's articles of association. In response to the detention of this senior executive, the company has properly arranged the relevant work. The chairman, the remaining directors, and the senior management team are all performing their duties normally on duty, the operation of the board of directors is not disrupted, and the company's production and operations remain normal. The matter will not have a material impact on the company's production, operations, and management.
Lu Chuanyou is a core management figure who grew up within Harbin Pharmaceutical and has long been in charge of the group's pharmaceutical segment. Pharmaceutical Factory No. 6 and Sanjing Pharmaceutical are both well-known entities under Harbin Pharmaceutical and have been important pillars of the group's past revenue and brand. The fact that the group's president has now been placed under investigation and detention by a supervisory authority has also drawn market attention to the details of the case and the reasons involved. However, as of now, Harbin Pharmaceutical's announcement has not disclosed the specific reasons for the investigation into Lu Chuanyou, and the progress of the relevant investigation awaits further release by the supervisory authority.
In the capital market, news that a listed company executive has been detained often easily triggers fluctuations in investor sentiment. Harbin Pharmaceutical promptly made clear in its announcement that its operating fundamentals are stable, aiming to send a signal to the market and isolate personal case risks from the listed company's business risks.
From a corporate governance perspective, a core executive being involved in a supervisory case also tests a listed company's internal control and emergency management capabilities. Harbin Pharmaceutical stated that its internal governance system is complete and that the existing management can continue to complete various operational tasks and ensure business continuity.
The pharmaceutical industry has continued to intensify anti-corruption efforts in recent years, and investigations into pharmaceutical company executives are not uncommon. Areas such as pharmaceutical procurement and sales, project management, and corporate operations are all key targets of supervision. Lu Chuanyou has worked deeply in Harbin Pharmaceutical for many years and held operational and management authority. The follow-up conclusions of this investigation may affect the market's scrutiny of Harbin Pharmaceutical Group's internal management.
For investors, it is necessary to distinguish between personal disciplinary and legal violations and the listed company's responsibility as an operating entity. Harbin Pharmaceutical's current production and operations have not yet been affected, but in the future it will be necessary to continue to pay attention to the supervisory authority's investigation results, the listed company's information disclosure, and the progress of personnel adjustments. If subsequent investigations find that the case involves the listed company's business, this may bring new variables. Harbin Pharmaceutical will also continue to follow the progress of the matter in accordance with regulatory requirements and timely fulfill its information disclosure obligations.